A background interview on MetrioPharm’s Phase II study
Dr. Petra Schulz, Senior Manager Drug Development at MetrioPharm spoke to us about the ongoing Phase II clinical trial and the details of the current press release
Photo: © F. Edler
MetrioPharm’s lead compound MP1032 entered Phase II clinical testing in early March. How has the study gone so far?
Dr. Petra Schulz: The most important goal of a large Phase II study continues to be to test the safety of the drug, i.e. whether the patients tolerate it well. So far, nobody has had to discontinue the study after taking MP1032, which is a good signal. The other important objectives – proof of efficacy and the search for the optimal dosage – are still unknown, because at the moment the study is blinded.
This week there was a...
